AHC0881

antibody from Invitrogen Antibodies

Targeting: CXCL8 3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1

ELISA

Immunohistochemistry

Blocking/Neutralizing

Antibody data

Submit

Validation data

Product number: AHC0881 - Provider product page
Provider: Invitrogen Antibodies
Product name: IL-8 (CXCL8) Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Purifed from natural sources
Description: Centrifuge vial prior to opening. Reconstitute in sterile water to 0.1-1.0 mg/mL.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µg
Storage: -20°C

CXCL8 protein structure - AHC0881 shown in red.

Supportive validation

Supportive validation

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Triple immunofluorescence costaining of frozen right peritoneal tissues were stained with CD68 (red), CD31 (blue), and keratin (CK) (green) antibodies (Rows 1 & 2) Row 1, peritoneal cells from a patient with EOC (ID 266 m) appear yellow from the colocalization of CD68 (red) and CK (green) on some surface mesothelial cells. CD31 staining (blue) indicates endothelial cells just under the mesothelium. Row 2, peritoneal cells from a patient with benign cystic teratoma of the ovary (ID 283b) show prominent staining for keratin in the single cell mesothelial layer but no staining for CD68 staining (red) and positive staining for endothelial cells (blue). Rows 3 and 4, peritoneal cells from patient ID#235 showed colocalization of CD68 (blue) and CD163 (green) appearing cyan color; CD68 (blue) and CXCL8 (red) costaining showed magenta effect and no color changed in CD163+ cells (green). Images were analyzed by confocal laser scanning microscopy (magnification 400x). H&E stained sections are shown for comparison.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Immunohistochemical expression of IL-8 (a), CXCR2 (b), IL-6 (c), tyrosine p-STAT-3 (d, e), SOCS-3 (f), and VEGF (g, h) in lymph nodes from CLL patients. (a) A CLL case with very few scattered IL-8 positive lymphoid cells. The inset shows an IL-8 positive cell in a higher magnification. Note the positive endothelial cells. (b) CXCR2 expression in a CLL lymph node. (c) IL-6 expression homogeneously distributed throughout the lymphoid tissue. (d) Tyrosine p-STAT-3 in a case showing a more pronounced immunoreactivity in the PCs. Note that endothelial cells are strongly positive. (e) Scattered tyrosine p-STAT-3 positive lymphoid cells along with positive endothelial cells in a CLL case. (f) Higher SOCS-3 expression in the PC in a CLL case. (g) (h) Pronounced VEGF immunoexpression in the PCs compared with the area outside the PCs. Higher magnification (h) showing the cytoplasmic immunoreactivity of VEGF. (PC: proliferation centers; E: endothelial cells).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Representative expression status for ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, serpine1 and IL8 levels in tumor tissue. Insert Representative expression status for ANG, CA9, MMP9, MMP10, SERPINA1, APOE, SDC1, VEGFA, serpine1 and IL-8 levels in benign tissue. All images were captured at 400x magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Representative expression status for ANG, CA9, MMP9, MMP10, A1AT, APOE, SDC1, VEGFA, PAI1 and IL8 in high-grade non-muscle invasive bladder tumor. Representative expression status for ANG, CA9, MMP9, MMP10, A1AT, APOE, SDC1, VEGFA, PAI1 and IL8 levels in benign tissue noted in square insert image. All images were captured at 400x magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 6 Figure GGA and rM180-treated hPDLCs promote angiogenesis in HUVECs. For the tube formation assay, HUVECs were cultured in matrigel-coated 96-well plates, and the supernatants from hPDLCs that were stimulated with or without GGA, rM180, or GGA + rM180 were added to the HUVECs (A) in the absence or (C) presence of neutralizing anti-Areg, anti-IL-8, anti-MCP-1, and anti-IL-6; (B) in the presence of the isotype control for 12 h at 37degC. (D) Tube formation was evaluated by counting the number of capillary tubes formed in at least 10 randomly selected fields per well. Scale bar = 200 mum. Data are represented as mean +- SD . n = 5. GGA, geranylgeranylacetone; hPDLC, human periodontal ligament cell; HUVEC, human umbilical vein endothelial cell. * p < .05; ** p < .01; *** p < .001

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Images of representative IHC staining for factors in primary melanoma (A) and metastatic melanoma (B).